BACKGROUND: Animal models that closely mimic clinical disease can be exploited to hasten the pace of translational research. To this end, we have defined windows of opportunity in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer as a paradigm for designing pre-clinical trials. METHODS: The incidence of cancer, metastasis, and distribution of pathology were examined as a function of time in TRAMP mice. The expression of various markers of differentiation were characterized. RESULTS: The TRAMP model develops progressive, multifocal, and heterogeneous disease. Each lobe of the prostate progressed at a different rate. Cytokeratin 8, E-cadherin, and androgen receptor (AR) were expressed during cancer progression but levels were reduced or absent in late stage disease. A distinct epithelial to neuroendocrine (ENT) shift was observed to be a stochastic event related to prostate cancer progression in TRAMP. CONCLUSIONS: This study will serve as the basis for the rational design of pre-clinical studies with genetically engineered mouse models. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: Animal models that closely mimic clinical disease can be exploited to hasten the pace of translational research. To this end, we have defined windows of opportunity in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer as a paradigm for designing pre-clinical trials. METHODS: The incidence of cancer, metastasis, and distribution of pathology were examined as a function of time in TRAMPmice. The expression of various markers of differentiation were characterized. RESULTS: The TRAMP model develops progressive, multifocal, and heterogeneous disease. Each lobe of the prostate progressed at a different rate. Cytokeratin 8, E-cadherin, and androgen receptor (AR) were expressed during cancer progression but levels were reduced or absent in late stage disease. A distinct epithelial to neuroendocrine (ENT) shift was observed to be a stochastic event related to prostate cancer progression in TRAMP. CONCLUSIONS: This study will serve as the basis for the rational design of pre-clinical studies with genetically engineered mouse models. Copyright 2003 Wiley-Liss, Inc.
Authors: Andrew C Dudley; Taturo Udagawa; Juan M Melero-Martin; Shou-Ching Shih; Adam Curatolo; Marsha A Moses; Michael Klagsbrun Journal: Blood Date: 2010-05-07 Impact factor: 22.113
Authors: Arnold I Chin; Andrea K Miyahira; Anthony Covarrubias; Juli Teague; Beichu Guo; Paul W Dempsey; Genhong Cheng Journal: Cancer Res Date: 2010-03-16 Impact factor: 12.701
Authors: Gaia Bistulfi; Barbara A Foster; Ellen Karasik; Bryan Gillard; Jeff Miecznikowski; Vineet K Dhiman; Dominic J Smiraglia Journal: Cancer Prev Res (Phila) Date: 2011-08-11
Authors: Arthur C-K Chung; Suoling Zhou; Lan Liao; Jean Ching-Yi Tien; Norman M Greenberg; Jianming Xu Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Simon Hu; Michael Lustig; Asha Balakrishnan; Peder E Z Larson; Robert Bok; John Kurhanewicz; Sarah J Nelson; Andrei Goga; John M Pauly; Daniel B Vigneron Journal: Magn Reson Med Date: 2010-02 Impact factor: 4.668
Authors: Shannon R Morey Kinney; Dominic J Smiraglia; Smitha R James; Michael T Moser; Barbara A Foster; Adam R Karpf Journal: Mol Cancer Res Date: 2008-07-30 Impact factor: 5.852